RATIONALE: Abuse of synthetic cathinones, popularized as "bath salts," has increased dramatically in the USA since their debut in 2010. Preclinical behavioral studies may clarify determinants of the abuse-related effects produced by these compounds. OBJECTIVES: This study examined behavioral effects of (±)-methcathinone, (±)-3,4-methylenedioxypyrovalerone (MDPV), (±)-3,4-methylenedioxymethcathinone (methylone), and (±)-4-methylmethcathinone (mephedrone) in rats using intracranial self-stimulation (ICSS). METHODS: Male Sprague-Dawley rats (n = 18) with electrodes targeting the medial forebrain bundle responded for multiple frequencies of brain stimulation and were tested in two phases. First, dose-effect curves for methcathinone (0.1-1.0 mg/kg), MDPV (0.32-3.2 mg/kg), methylone (1.0-10 mg/kg), and mephedrone (1.0-10 mg/kg) were determined. Second, time courses were determined for effects produced by the highest dose of each compound. RESULTS: Methcathinone produced dose- and time-dependent facilitation of ICSS. MDPV, methylone, and mephedrone produced dose- and time-dependent increases in low rates of ICSS maintained by low brain stimulation frequencies, but also produced abuse-limiting depression of high ICSS rates maintained by high brain stimulation frequencies. Efficacies to facilitate ICSS were methcathinone ≥ MDPV ≥ methylone > mephedrone. Methcathinone was the most potent compound, and MDPV was the longest acting compound. CONCLUSIONS: All compounds facilitated ICSS at some doses and pretreatment times, which is consistent with abuse liability for each of these compounds. However, efficacies of compounds to facilitate ICSS varied, with methcathinone displaying the highest efficacy and mephedrone displaying the lowest efficacy to facilitate ICSS.
RATIONALE: Abuse of synthetic cathinones, popularized as "bath salts," has increased dramatically in the USA since their debut in 2010. Preclinical behavioral studies may clarify determinants of the abuse-related effects produced by these compounds. OBJECTIVES: This study examined behavioral effects of (±)-methcathinone, (±)-3,4-methylenedioxypyrovalerone (MDPV), (±)-3,4-methylenedioxymethcathinone (methylone), and (±)-4-methylmethcathinone (mephedrone) in rats using intracranial self-stimulation (ICSS). METHODS: Male Sprague-Dawley rats (n = 18) with electrodes targeting the medial forebrain bundle responded for multiple frequencies of brain stimulation and were tested in two phases. First, dose-effect curves for methcathinone (0.1-1.0 mg/kg), MDPV (0.32-3.2 mg/kg), methylone (1.0-10 mg/kg), and mephedrone (1.0-10 mg/kg) were determined. Second, time courses were determined for effects produced by the highest dose of each compound. RESULTS:Methcathinone produced dose- and time-dependent facilitation of ICSS. MDPV, methylone, and mephedrone produced dose- and time-dependent increases in low rates of ICSS maintained by low brain stimulation frequencies, but also produced abuse-limiting depression of high ICSS rates maintained by high brain stimulation frequencies. Efficacies to facilitate ICSS were methcathinone ≥ MDPV ≥ methylone > mephedrone. Methcathinone was the most potent compound, and MDPV was the longest acting compound. CONCLUSIONS: All compounds facilitated ICSS at some doses and pretreatment times, which is consistent with abuse liability for each of these compounds. However, efficacies of compounds to facilitate ICSS varied, with methcathinone displaying the highest efficacy and mephedrone displaying the lowest efficacy to facilitate ICSS.
Authors: Michael H Baumann; Mario A Ayestas; John S Partilla; Jacqueline R Sink; Alexander T Shulgin; Paul F Daley; Simon D Brandt; Richard B Rothman; Arnold E Ruoho; Nicholas V Cozzi Journal: Neuropsychopharmacology Date: 2011-12-14 Impact factor: 7.853
Authors: J Elliott Robinson; Abigail E Agoglia; Eric W Fish; Michael C Krouse; C J Malanga Journal: Behav Brain Res Date: 2012-06-21 Impact factor: 3.332
Authors: Gregory C Hadlock; Katy M Webb; Lisa M McFadden; Pei Wen Chu; Jonathan D Ellis; Scott C Allen; David M Andrenyak; Paula L Vieira-Brock; Christopher L German; Kevin M Conrad; Amanda J Hoonakker; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein Journal: J Pharmacol Exp Ther Date: 2011-08-02 Impact factor: 4.030
Authors: Christopher L German; Mario E Alburges; Amanda J Hoonakker; Annette E Fleckenstein; Glen R Hanson Journal: Synapse Date: 2014-09-08 Impact factor: 2.562
Authors: Charles W Schindler; Eric B Thorndike; Steven R Goldberg; Kurt R Lehner; Nicholas V Cozzi; Simon D Brandt; Michael H Baumann Journal: Psychopharmacology (Berl) Date: 2015-08-29 Impact factor: 4.530
Authors: Farhana Sakloth; Elizabeth Leggett; Megan J Moerke; E Andrew Townsend; Matthew L Banks; S Stevens Negus Journal: Exp Clin Psychopharmacol Date: 2019-01-10 Impact factor: 3.157
Authors: Jacques D Nguyen; Shawn M Aarde; Maury Cole; Sophia A Vandewater; Yanabel Grant; Michael A Taffe Journal: Neuropsychopharmacology Date: 2016-06-09 Impact factor: 7.853
Authors: Alexandre Vouga; Ryan A Gregg; Maryah Haidery; Anita Ramnath; Hassan K Al-Hassani; Christopher S Tallarida; David Grizzanti; Robert B Raffa; Garry R Smith; Allen B Reitz; Scott M Rawls Journal: Neuropharmacology Date: 2014-12-09 Impact factor: 5.250